ERYTHROPOIESIS REACTION TO TUMOR GROWTH IN LUNG CANCER PATIENTS

Background. In addition to the transport of oxygen in tissues, erythrocytes participate in maintaining homeostasis therefore their qualitative and quantitative characterization may reflect a number of changes occurring in the body. The aim of the study was to investigate the erythrone state and reaction of red blood cells of hematopoiesis in patients with lung cancer with the assessment of ability to use such reactions as predictive signs of aggressiveness of the tumor process. Results. Clinical material indicating the presence of reaction of erythropoiesis and enzymatic antioxidant system to tumor growth in patients with lung cancer was obtained. Pathological changes in the erythrone system, including changes in the concentration of hypoxia-inducible factor 1α, quantitative and morphological characteristics of red blood cells and reticulocytes, hemoglobin concentration and the activity of superoxide dismutase correlated with tumor aggressiveness and more severe clinical status of patients. Сonclusion. A comprehensive assessment of erythropoiesis is believed can be used in selection of criteria for predicting treatment response and patients survival.

lung cancer, tumor aggressiveness, hypoxia-inducible factor 1α, erythroid hematopoiesis stimulation, polycythemia, high acid resistance of erythrocytes

1. Edge S., Byrd D.R., Compton C.C., Fritz A.G., Greene F.L., Trotti A. AJCC Cancer Staging Manual, 7-th ed. New York: Spriger. 2010; 730 p.

2. Semina О.V., Semenets Т.N., Zamulaeva I.А., Selivanova Е.I., Ilina Т.P., Malyutina Ya.V., Semin D.Yu., Deigin V.I., Saenko А.S. Gamma dipeptide D-GLU-D-TRP (thymodepressin) inhibits migration of CD34+ cells from the bone marrow into the peripheral blood during tumor growth. Bull Exp Biol Med. 2008; 7 (146): 105–108. [in Russian]

3. Osinskiy S., Vaupel P. Micriphysiology of tumors (metabolic microenvironment of tumor cells: characteristics, influence on tumor progression, clinical application). Kiev, 2009; 254 p. [in Russian]

4. Jiang J., Tang Y.L., Liang X.H. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther. 2011 Apr 15; 11 (8): 714–23.

5. Lopez-Lazaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med. 2010 Mar; 16 (3–4): 144–53. doi: 10.2119/molmed.2009.00162.

6. Mucaj V., Shay J.E., Simon M.C. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. 2012 May; 95 (5): 464–70. doi: 10.1007/ s12185-012-1070-5.

7. Nozawa-Suzuki N., Nagasawa H., Ohnishi K., Morishige K. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer. Biochem Biophys Res Commun. 2015 Feb 20; 457 (4): 706–11. doi: 10.1016/j.bbrc.2015.01.053.

8. Rohwer N., Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011 Jun; 14 (3): 191–201. doi: 10.1016/j. drup.2011.03.001.

9. Zhao J., Du F., Luo Y., Shen G., Zheng F., Xu B. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treat Rev. 2015 Jul; 41 (7): 623–33. doi: 10.1016/j. ctrv.2015.05.004.

10. Terskov I.А., Gitelzon I.I. The method of chemical (acid) erythrograms. Biophysics. 1957; 11 (2): 259–266. [in Russian]

11. Izmestyeva О.S., Luzyanina А.А., Ershova I.L., Zhavoronkov L.P. Study of the effect of low-dose γ-irradiation on functional state of peripheral blood erythrocytes. Radiat Biol. Radioecology. 2014; 5 (54): 493. [in Russian]

12. Korolyuk М.А., Ivanova L.I., Maiorova I.G., Tokarev V.Е. A method of determining the catalase activity. Laboratornoe delo. 1988; 1: 16–19. [in Russian]

13. Semenza G.L. Involvement of Hypoxia-Inducible Factor 1 in Human Cancer. Internal Medicine. 2002; 41 (2): 79–83.

14. Semenza G.L. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood. 2009; 114 (10): 2015–2019.

15. Hung J.J., Yang M.H., Hsu H.S., Hsu W.H., Liu J.S., Wu K.J. Prognostic significance of hypoxia-inducible factor 1 alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax. 2009; 64 (12): 1082–1089.